Search research articles
Contact Us
Filters
Showing results (71-80 of 106) with videos related to
Page
of 11
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 25, 2012
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab
Elaine M Jagoda, Lixin Lang, Veerendra Bhadrasetty, et al.
Cancer Cell
|
October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen, Frances Shanahan, Mark Merchant, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 29, 2015
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors
Anneleen Daemen, David Peterson, Nisebita Sahu, et al.
Cancer Research
|
July 3, 2025
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
Ashley V DiMarco, Mirunalini Ravichandran, Jeff Lau, et al.
Toxicology and Applied Pharmacology
|
November 13, 2012
Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor
Dolores Diaz, Kevin A Ford, Dylan P Hartley, et al.
Cancer Research
|
April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment
Jonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Cancer Research
|
August 17, 2019
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer
Steffan Vartanian, James Lee, Christiaan Klijn, et al.
ACS Medicinal Chemistry Letters
|
May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor
Malcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
Molecular Cancer Therapeutics
|
August 26, 2021
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
Paul Rossman, Tanja S Zabka, Audrey Ruple, et al.
Nature
|
August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 106) with videos related to
Sort By:
Page
of 11
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 25, 2012
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab
Elaine M Jagoda, Lixin Lang, Veerendra Bhadrasetty, et al.
Cancer Cell
|
October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen, Frances Shanahan, Mark Merchant, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 29, 2015
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors
Anneleen Daemen, David Peterson, Nisebita Sahu, et al.
Cancer Research
|
July 3, 2025
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
Ashley V DiMarco, Mirunalini Ravichandran, Jeff Lau, et al.
Toxicology and Applied Pharmacology
|
November 13, 2012
Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor
Dolores Diaz, Kevin A Ford, Dylan P Hartley, et al.
Cancer Research
|
April 9, 2020
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment
Jonathan M Harnoss, Adrien Le Thomas, Mike Reichelt, et al.
Cancer Research
|
August 17, 2019
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer
Steffan Vartanian, James Lee, Christiaan Klijn, et al.
ACS Medicinal Chemistry Letters
|
May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor
Malcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
Molecular Cancer Therapeutics
|
August 26, 2021
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma
Paul Rossman, Tanja S Zabka, Audrey Ruple, et al.
Nature
|
August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Page
of 11